Treatment strategies for the behavioral symptoms of Alzheimer's disease: Focus on early pharmacologic intervention

Pharmacotherapy

Volumn 27, Issue 3, 2007, Pages 399-411

  Beier, Manju T ^a  

^a UNIVERSITY OF MICHIGAN   (United States)

Author keywords

Alzheimer's disease; Behavior; Cholinesterase inhibitors; Memantine; Neuropsychiatric Inventory

Indexed keywords

ARIPIPRAZOLE; CARBAMAZEPINE; CHOLINESTERASE INHIBITOR; DONEPEZIL; GALANTAMINE; MEMANTINE; NEUROLEPTIC AGENT; OLANZAPINE; PLACEBO; RISPERIDONE; SEROTONIN UPTAKE INHIBITOR; VALPROATE SEMISODIUM;

ABNORMAL DREAMING; ALZHEIMER DISEASE; BEHAVIOR DISORDER; BRADYCARDIA; CLINICAL TRIAL; CONFUSION; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DISEASE SEVERITY; DIZZINESS; DRUG SAFETY; DRUG TOLERABILITY; EARLY DIAGNOSIS; FALL RISK; FATIGUE; GAIT DISORDER; HEADACHE; HIP FRACTURE; HUMAN; INSOMNIA; MAJOR CLINICAL STUDY; MUSCLE CRAMP; MUSIC THERAPY; NAUSEA; ORIENTATION; QUALITY OF LIFE; RECREATION; REVIEW; SIDE EFFECT; SOCIAL INTERACTION; SYNCOPE; TARDIVE DYSKINESIA; VOMITING; WEIGHT REDUCTION;

ALZHEIMER DISEASE; CHOLINESTERASE INHIBITORS; GALANTAMINE; HUMANS; INDANS; MEMANTINE; MENTAL DISORDERS; PIPERIDINES; TIME FACTORS;

EID: 33847246944     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.27.3.399     Document Type: Review

References (98)

1. Galasko D. An integrated approach to the management of Alzheimer's disease: assessing cognition, function and behaviour. Eur J Neurol 1998;5(suppl 4):S9-17.
2. Hebert LE, Scherr PA, Bienias JL, Bennett DA, Evans DA. Alzheimer disease in the US population: prevalence estimates using the 2000 census. Arch Neurol 2003;60:1119-22.
3. Evans DA, Funkenstein HH, Albert MS, et al. Prevalence of Alzheimer's disease in a community population of older persons: higher than previously reported. JAMA 1989;262:2551-6.
4. Krauss NA, Altman BM. Research findings no. 5: characteristics of nursing home residents-1996. Agency for Healthcare Research and Quality. Available from www.meps. ahrq.gov/mepsweb/data_files/publications/rf5/rf5.pdf. Accessed September 15, 2006.
5. Jost BC, Grossberg GT. The evolution of psychiatric symptoms in Alzheimer's disease: a natural history study. J Am Geriatr Soc 1996;44:1078-81.
6. Mega MS, Cummings JL, Fiorello T, Gornbein J. The spectrum of behavioral changes in Alzheimer's disease. Neurology 1996;46:130-5.
7. Levy ML, Cummings JL, Kahn-Rose R. Neuropsychiatric symptoms and cholinergic therapy for Alzheimer's disease. Gerontology 1999;45(suppl 1):15-22.
8. Aggarwal N, Vass AA, Minardi HA, Ward R, Garfield C, Cybyk B. People with dementia and their relatives: personal experiences of Alzheimer's and of the provision of care. J Psychiatr Ment Health Nurs 2003;10:187-97.
9. Steele C, Rovner B, Chase GA, Folstein M. Psychiatric symptoms and nursing home placement of patients with Alzheimer's disease. Am J Psychiatry 1990;147:1049-51.
10. Coen RF, Swanwick GR, O'Boyle CA, Coakley D. Behaviour disturbance and other predictors of caregiver burden in Alzheimer's disease. Int J Geriatr Psychiatry 1997;12:331-6.
11. Moore MJ, Zhu CW, Clipp EC. Informal costs of dementia care: estimates from the national longitudinal caregiver study. J Gerontol B Psychol Sci Soc Sci 2001;56B:S219-28.
12. Alzheimer's Association. Behavioral and psychiatric Alzheimer's symptoms. Alzheimer's Association fact sheet. Available from www.alz.org/Resources/FactSheets/fs_ behavioralandpsychiatric.pdf. Accessed September 15, 2006.
13. Aronstein Z, Olsen R, Schulman E. The nursing assistants use of recreational interventions for behavioral management of residents with Alzheimer's disease. Am J Alzheimers Dis 1996;11:26-31.
14. Churchill M, Safaoui J, McCabe BW, Baun MM. Using a therapy dog to alleviate the agitation and desocialization of people with Alzheimer's disease. J Psychosoc Nurs Ment Health Serv 1999;37:16-22.
15. Cohen-Mansfield J, Werner P. Management of verbally disruptive behaviors in nursing home residents. J Gerontol A Biol Sci Med Sci 1997;52A:M369-77.
16. Cohen-Mansfield J. Nonpharmacologic interventions for inappropriate behaviors in dementia: a review, summary, and critique. Am J Geriatr Psychiatry 2001;9:361-81.
17. Desai AK, Grossberg GT. Recognition and management of behavioral disturbances in dementia. Prim Care Companion J Clin Psychiatry 2001;3:93-109.
18. Gerdner L. An individualized music intervention for agitation. J Am Psychiatr Nurses Assoc 1997;3:177-84.
19. Holmberg SK. Evaluation of a clinical intervention for wanderers on a geriatric nursing unit. Arch Psychiatr Nurs 1997;11:21-8.
20. Ballard CG, O'Brien JT, Reichelt K, Perry EK. Aromatherapy as a safe and effective treatment for the management of agitation in severe dementia: the results of a double-blind, placebo-controlled trial with melissa. J Clin Psychiatry 2002;63:553-8.
21. Mishima K, Okawa M, Hishikawa Y, Hozumi S, Hori, H, Takahashi K. Morning bright light therapy for sleep and behavior disorders in elderly patients with dementia. Acta Psychiatr Scand 1994;89:1-7.
22. Namazi KH, Gwinnup PB, Zadorozny CA. A low intensity exercise/movement program for patients with Alzheimer's disease: the TEMP-AD protocol. J Aging Phys Act 1994;2:80-92.
23. Osterweil D. Alzheimer's disease in the long-term care setting: management of behavioral disturbances with cholinesterase inhibitors. Ann Long Term Care 2004;12:18-24.
24. Rogers JC, Holm MB, Burgio LD, et al. Improving morning care routines of nursing home residents with dementia. J Am Geriatr Soc 1999;47:1049-57.
25. Sobel BP. Bingo vs physical intervention in stimulating short-term cognition in Alzheimer's disease patients. Am J Alzheimers Dis Other Demen 2001;16:115-20.
26. Sultzer DL, Cummings JL. Alzheimer's disease. In: Rakel R, Conn H, eds. Current therapy: latest approved methods of treatment for the practicing physician. Philadelphia: WB Saunders; 1993:838-40.
27. Ray WA, Taylor JA, Meador KG, et al. Reducing antipsychotic drug use in nursing homes: a controlled trial of provider education. Arch Intern Med 1993;153:713-21.
28. Shinosaki K, Nishikawa T, Takeda M. Neurobiological basis of behavioral and psychological symptoms in dementia of the Alzheimer type. Psychiatry Clin Neurosci 2000;54:611-20.
29. Holroyd S, Shepherd ML, Downs JH III. Occipital atrophy is associated with visual hallucinations in Alzheimer's disease. J Neuropsychiatry Clin Neurosci 2000;12:25-8.
30. Craig AH, Cummings JL, Fairbanks L, et al. Cerebral blood flow correlates of apathy in Alzheimer disease. Arch Neurol 1996;53:1116-20.
31. Nakano S, Yamashita F, Matsuda H, Kodama C, Yamada T. Relationship between delusions and regional cerebral blood flow in Alzheimer's disease. Dement Geriatr Cogn Disord 2006;21:16-21.
32. Lanctot KL, Herrmann N, Nadkarni NK, Leibovitch FS, Caldwell CB, Black SE. Medial temporal hypoperfusion and aggression in Alzheimer disease. Arch Neurol 2004;61:1731-7.
33. Mega MS, Dinov ID, Lee L, et al. Orbital and dorsolateral frontal perfusion defect associated with behavioral response to cholinesterase inhibitor therapy in Alzheimer's disease. J Neuropsychiatry Clin Neurosci 2000;12:209-18.
34. Benoit M, Clairet S, Koulibaly PM, Darcourt J, Robert PH. Brain perfusion correlates of the apathy inventory dimensions of Alzheimer's disease. Int J Geriatr Psychiatry 2004;19:864-9.
35. Cummings JL, Kaufer D. Neuropsychiatric aspects of Alzheimer's disease: the cholinergic hypothesis revisited. Neurology 1996;47:876-83.
36. Staff RT, Gemmell HG, Shanks MF, Murray AD, Venneri A. Changes in the rCBF images of patients with Alzheimer's disease receiving donepezil therapy. Nucl Med Commun 2000;21:37-41.
37. Nakano S, Asada T, Matsuda H, Uno M, Takasaki M. Donepezil hydrochloride preserves regional cerebral blood flow in patients with Alzheimer's disease. J Nucl Med 2001;42:1441-5.
38. Venneri A, Shanks MF, Staff RT, et al. Cerebral blood flow and cognitive responses to rivastigmine treatment in Alzheimer's disease. Neuroreport 2002;13:83-7.
39. Sultzer DL, Mahler ME, Mandelkern MA, et al. The relationship between psychiatric symptoms and regional cortical metabolism in Alzheimer's disease. J Neuropsychiatry Clin Neurosci 1995;7:476-84.
40. Sultzer DL, Brown CV, Mandelkern MA, et al. Delusional thoughts and regional frontal/temporal cortex metabolism in Alzheimer's disease. Am J Psychiatry 2003;160:341-9.
41. Cummings JL, Mega M, Gray K, Rosenberg-Thompson S, Carusi DA, Gornbein J. The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia. Neurology 1994;44:2308-14.
42. Wood S, Cummings JL, Hsu MA, et al. The use of the neuropsychiatric inventory in nursing home residents: characterization and measurement. Am J Geriatr Psychiatry 2000;8:75-83.
43. Tariot PN, Cummings JL, Katz IR, et al. A randomized, double-blind, placebo-controlled study of the efficacy and safety of donepezil in patients with Alzheimer's disease in the nursing home setting. J Am Geriatr Soc 2001;49:1590-9.
44. Kaduszkiewicz H, Zimmermann T, Beck-Bornholdt HP, van den Bussche H. Cholinesterase inhibitors for patients with Alzheimer's disease: systematic review of randomised clinical trials. BMJ 2005;331:321-7.
45. Doody RS, Stevens JC, Beck C, et al. Practice parameter: management of dementia (an evidence-based review): report of the quality standards subcommittee of the American Academy of Neurology. Neurology 2001;56:1154-66.
46. Burns A, Rossor M, Hecker J, et al. The effects of donepezil in Alzheimer's disease: results from a multinational trial. Dement Geriatr Cogn Disord 1999;10:237-44.
47. Feldman H, Gauthier S, Hecker J, Vellas B, Subbiah P, Whalen E. A 24-week, randomized, double-blind study of donepezil in moderate to severe Alzheimer's disease. Neurology 2001;57:613-20.
48. Corey-Bloom J, Anand R, Veach J. A randomized trial evaluating the efficacy and safety of ENA 713 (rivastigmine tartrate), a new acetylcholinesterase inhibitor, in patients with mild to moderately severe Alzheimer's disease. Int J Geriatr Psychopharmacol 1998;1:55-65.
49. Holmes C, Wilkinson D, Dean C, et al. The efficacy of donepezil in the treatment of neuropsychiatric symptoms in Alzheimer disease. Neurology 2004;63:214-19.
50. Mohs RC, Doody RS, Morris JC, et al. A 1-year, placebo-controlled preservation of function survival study of donepezil in AD patients. Neurology 2001;57:481-8.
51. Raskind MA, Peskind ER, Wessel T, Yuan W. Galantamine in AD: a 6-month randomized, placebo-controlled trial with a 6-month extension. Neurology 2000;54:2261-8.
52. Rosier M, Anand R, Cicin-Sain A, et al. Efficacy and safety of rivastigmine in patients with Alzheimer's disease: international randomised controlled trial. BMJ 1999;318:633-8.
53. Tariot PN, Solomon PR, Morris JC, Kershaw P, Lilienfeld S, Ding C. A 5-month, randomized, placebo-controlled trial of galantamine in AD. Neurology 2000;54:2269-76.
54. Rockwood K, Mintzer J, Truyen L, Wessel T, Wilkinson D. Effects of a flexible galantamine dose in Alzheimer's disease: a randomised, controlled trial. J Neurol Neurosurg Psychiatry 2001;71:589-95.
55. Aupperle PM, Koumaras B, Chen M, Rabinowicz A, Mirski D. Long-term effects of rivastigmine treatment on neuropsychiatric and behavioral disturbances in nursing home residents with moderate to severe Alzheimer's disease: results of a 52-week open-label study. Curr Med Res Opin 2004;20:1605-12.
56. Sink KM, Holden KF, Yaffe K. Pharmacological treatment of neuropsychiatric symptoms of dementia: a review of the evidence. JAMA 2005;293:596-608.
57. Winblad B, Kilander L, Eriksson S, et al. Donepezil in patients with severe Alzheimer's disease: double-blind, parallel-group, placebo-controlled study. Lancet 2006;367:1057-65.
58. Peskind ER, Potkin SG, Pomara N, et al. Memantine treatment in mild to moderate Alzheimer disease: a 24-week randomized, controlled trial. Am J Geriatr Psychiatry 2006;14:704-15.
59. Tariot PN, Farlow MR, Grossberg GT, Graham SM, McDonald S, Gergel I. Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial. JAMA 2004;291:317-24.
60. Reisberg B, Doody R, Stoffler A, Schmitt F, Ferris S, Mobius HJ. Memantine in moderate-to-severe Alzheimer's disease. N Engl J Med 2003;348:1333-41.
61. Wilcock G, Howe I, Coles H, et al. A long-term comparison of galantamine and donepezil in the treatment of Alzheimer's disease. Drugs Aging 2003;20:777-89.
62. Courtney C, Farrell D, Gray R, et al. Long-term donepezil treatment in 565 patients with Alzheimer's disease (AD2000): randomised double-blind trial. Lancet 2004;363:2105-15.
63. Birks J. Cholinesterase inhibitors for Alzheimer's disease. [Cochrane review]. In: The Cochrane Library, Issue 1, 2006 [online]. Available from www.mrw.interscience.wiley.com/cochrane/clsysrev/articles/CD005593/pdf_fs. html. Accessed September 15, 2006.
64. Trinh NH, Hoblyn J, Mohanty S, Yaffe K. Efficacy of cholinesterase inhibitors in the treatment of neuropsychiatric symptoms and functional impairment in Alzheimer disease: a meta-analysis. JAMA 2003;289:210-16.
65. Cummings JL, Koumaras B, Chen M, Mirski D. Effects of rivastigmine treatment on the neuropsychiatric and behavioral disturbances of nursing home residents with moderate to severe probable Alzheimer's disease: a 26-week, multicenter, open-label study. Am J Geriatr Pharmacother 2005;3:137-48.
66. Khang P, Weintraub N, Espinoza RT. The use, benefits, and costs of cholinesterase inhibitors for Alzheimer's dementia in long-term care: are the data relevant and available? J Am Med Dir Assoc 2004;5:249-55.
67. Cummings JL. Alzheimer's disease. N Engl J Med 2004;351:56-67.
68. Cummings J, Schneider E, Tariot PN, et al. Behavioral effects of memantine in Alzheimer disease patients receiving donepezil treatment. Neurology 2006;67:57-63.
69. Forest Laboratories. Namenda (memantine) package insert. St. Louis, MO; 2005.
70. Daiello L, Beier M, Hoffmann V, Kennedy JS. Pharmacotherapy of behavioral and psychological symptoms of dementia: a review of atypical antipsychotics. Consult Pharm 2003;18:138-57.
71. Schneider LS. Pharmacologic management of psychosis in dementia. J Clin Psychiatry. 1999;60(suppl 8):54-60.
72. Ray WA, Griffin MR, Schaffner W, Baugh DK, Melton LJ III. Psychotropic drug use and the risk of hip fracture. N Engl J Med 1987;316:363-9.
73. Tinetti ME, Williams TF, Mayewski R. Fall risk index for elderly patients based on number of chronic disabilities. Am J Med 1986;80:429-34.
74. Street JS, Clark WS, Gannon KS, et al. Olanzapine treatment of psychotic and behavioral symptoms in patients with Alzheimer disease in nursing care facilities: a double-blind, randomized, placebo-controlled trial. The HGEU study group. Arch Gen Psychiatry 2000;57:968-76.
75. De Deyn PP, Carrasco MM, Deberdt W, et al. Olanzapine versus placebo in the treatment of psychosis with or without associated behavioral disturbances in patients with Alzheimer's disease. Int J Geriatr Psychiatry 2004;19:115-26.
76. Schneider LS, Tariot PN, Dagerman KS, et al. Effectiveness of atypical antipsychotic drugs in patients with Alzheimer's disease. N Engl J Med 2006;355:1525-38.
77. Cohen GD. Alzheimer's disease: managing behavioral problems in patients with progressive dementia. Geriatrics 2002;57:53-4.
78. Miller CH, Mohr F, Umbricht D, Woerner M, Fleischhacker WW, Lieberman JA. The prevalence of acute extrapyramidal signs and symptoms in patients treated with clozapine, risperidone, and conventional antipsychotics. J Clin Psychiatry 1998;59:69-75.
79. Rochon PA, Stukel TA, Sykora K, et al. Atypical antipsychotics and parkinsonism. Arch Intern Med 2005;165:1882-8.
80. Janssen Pharmaceutica. Risperdal (risperidone) package insert. Titusville, NJ; 2005.
81. Eli Lilly. Zyprexa (olanzapine) package insert. Indianapolis, IN; 2005.
82. Bristol-Myers Squibb and Otsuka America Pharmaceutical. Abilify (aripiprazole) package insert. Princeton, NJ, and Rockville, MD; 2005.
83. Smith DA, Beier MT. Association between risperidone treatment and cerebrovascular adverse events: examining the evidence and postulating hypotheses for an underlying mechanism. J Am Med Dir Assoc 2004;5:129-32.
84. Gill SS, Rochon PA, Herrmann N, et al. Atypical antipsychotic drugs and risk of ischaemic stroke: population based retrospective cohort study. BMJ 2005;330:445-8.
85. Food and Drug Administration, Center for Drug Evaluation and Research. Deaths with antipsychotics in elderly patients with behavioral disturbances. Available from www.fda.gov/cder/drug/advisory/antipsychotics.htm. Accessed September 15, 2006.
86. Schneider LS, Dagerman KS, Insel P. Risk of death with atypical antipsychotic drug treatment for dementia: meta-analysis of randomized placebo-controlled trials. JAMA 2004;294:1934-43.
87. Wang PS, Schneeweiss S, Avorn J, et al. Risk of death in elderly users of conventional vs atypical antipsychotic medications. N Engl J Med 2005;353:2335-41.
88. Gleason RP, Schneider LS. Carbamazepine treatment of agitation in Alzheimer's outpatients refractory to neuroleptics. J Clin Psychiatry 1990;51:115-18.
89. Lemke MR. Effect of carbamazepine on agitation in Alzheimer's inpatients refractory to neuroleptics. J Clin Psychiatry 1995;56:354-7.
90. Tariot PN, Erb R, Podgorski CA, et al. Efficacy and tolerability of carbamazepine for agitation and aggression in dementia. Am J Psychiatry 1998;155:54-61.
91. Olin JT, Fox LS, Pawluczyk S, Taggart NA, Schneider LS. A pilot randomized trial of carbamazepine for behavioral symptoms in treatment-resistant outpatients with Alzheimer disease. Am J Geriatr Psychiatry 2001;9:400-5.
92. Tariot PN, Schneider LS, Mintzer JE, et al. Safety and tolerability of divalproex sodium in the treatment of signs and symptoms of mania in elderly patients with dementia: results of a double-blind, placebo-controlled trial. Curr Ther Res Clin Exp 2001;62:51-67.
93. Porsteinsson AP, Tariot PN, Erb R, et al. Placebo-controlled study of divalproex sodium for agitation in dementia. Am J Geriatr Psychiatry 2001;9:58-66.
94. Porsteinsson AP, Tariot PN, Jakimovich LJ, et al. Valproate therapy for agitation in. dementia: open-label extension of a double-blind trial. Am J Geriatr Psychiatry 2003;11:434-40.
95. Meehan KM, Wang H, David SR, et al. Comparison of rapidly acting intramuscular olanzapine, lorazepam, and placebo: a double-blind, randomized study in acutely agitated patients with dementia. Neuropsychopharmacology 2002;26:494-504.
96. Alexopoulos GS, Jeste DV, Chung H, Carpenter D, Ross R, Docherty JP. The expert consensus guideline series: treatment of dementia and its behavioural disturbances. Postgrad Med (special report) January 2005.
97. Lopez OL, Becker JT, Wisniewski S, Saxton J, Kaufer DI, DeKosky ST. Cholinesterase inhibitor treatment alters the natural history of Alzheimer's disease. J Neurol Neurosurg Psychiatry 2002;72:310-14.
98. Geldmacher DS, Provenzano G, McRae T, Mastey V, Leni JR. Donepezil is associated with delayed nursing home placement in patients with Alzheimer's disease. J Am Geriatr Soc 2003;51:937-44.